Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe
Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.
You may also be interested in...
Facing civil and criminal charges over alleged price fixing in the US, Teva looks to have succeeded in removing itself from the spotlight in the civil proceedings, having previously been selected as a priority for trial. CEO Kåre Schultz weighed in on the latest development.
Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.
Sandoz has agreed to pay a $195m criminal penalty, the largest for a US antitrust case, as part of a deferred prosecution agreement with the US Department of Justice to resolve antitrust allegations as part of the country’s ongoing investigation into generic price-fixing.